Does ELTROMBOPAG OLAMINE Cause Malignant neoplasm progression? 26 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 26 reports of Malignant neoplasm progression have been filed in association with ELTROMBOPAG OLAMINE (ELTROMBOPAG). This represents 0.2% of all adverse event reports for ELTROMBOPAG OLAMINE.
26
Reports of Malignant neoplasm progression with ELTROMBOPAG OLAMINE
0.2%
of all ELTROMBOPAG OLAMINE reports
16
Deaths
7
Hospitalizations
How Dangerous Is Malignant neoplasm progression From ELTROMBOPAG OLAMINE?
Of the 26 reports, 16 (61.5%) resulted in death, 7 (26.9%) required hospitalization.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ELTROMBOPAG OLAMINE. However, 26 reports have been filed with the FAERS database.
What Other Side Effects Does ELTROMBOPAG OLAMINE Cause?
Platelet count decreased (3,419)
Death (2,797)
Drug ineffective (1,117)
Platelet count increased (980)
Fatigue (868)
Headache (750)
Nausea (584)
Diarrhoea (558)
Product use in unapproved indication (545)
Malaise (516)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which ELTROMBOPAG OLAMINE Alternatives Have Lower Malignant neoplasm progression Risk?
ELTROMBOPAG OLAMINE vs ELUXADOLINE
ELTROMBOPAG OLAMINE vs ELVITEGRAVIR
ELTROMBOPAG OLAMINE vs EMAPALUMAB
ELTROMBOPAG OLAMINE vs EMAPALUMAB-LZSG
ELTROMBOPAG OLAMINE vs EMEND